Skip to content

Bariatric Surgery vs. Lifestyle Modification for NASH

Bariatric Surgery vs. Lifestyle Modification: Effects Against Nonalcoholic Steatohepatitis Randomized Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04298736
Acronym
BeLEANeR
Enrollment
50
Registered
2020-03-06
Start date
2020-02-19
Completion date
2022-03-20
Last updated
2020-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NASH - Nonalcoholic Steatohepatitis

Brief summary

Randomized Controlled Trial comparing the effects of Bariatric Surgery vs. Lifestyle modification on NASH resolution.

Detailed description

Patients with biopsy-proven NASH will be randomized to either bariatric surgery or lifestyle interventions. After 1-year follow-up a liver biopsy will be done to evaluate NASH resolution

Interventions

PROCEDUREBariatric Surgery

laparoscopic Roux-en-Y gastric bypass or laparoscopic Sleeve Gastrectomy

BEHAVIORALLifestyle modification

guided low-calorie diet and physical activity.

Sponsors

Hospital de Clinicas de Porto Alegre
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Masking description

Blinded pathologist

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* BMI between 30 and 45 * with biopsy-proven NASH * with or without type 2 diabetes * that fit for bariatric surgery.

Exclusion criteria

* borderline NASH ou cirrhosis; * alcohol consumption (\> 20 g/day for men and \> 10 g/day for women, for the last 2 years); * other hepatic diseases (such as viral hepatitis, autoimmune hepatitis, drug-induced hepatic disease, Wilson's disease, hemochromatosis); * HIV infection; * unable to provide informed consent; * previous foregut or bariatric surgery; * malignancy; * patients that unfit for bariatric surgery.

Design outcomes

Primary

MeasureTime frameDescription
NASH resolution12 monthsNASH resolution evaluated by liver biopsy

Countries

Brazil

Contacts

Primary ContactGuilherme S Mazzini, MD, PhD
guimazzini@gmail.com+55(51)981364873

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026